IL314600A - Combination therapy for use in treatment of non-small cell lung cancer - Google Patents
Combination therapy for use in treatment of non-small cell lung cancerInfo
- Publication number
- IL314600A IL314600A IL314600A IL31460024A IL314600A IL 314600 A IL314600 A IL 314600A IL 314600 A IL314600 A IL 314600A IL 31460024 A IL31460024 A IL 31460024A IL 314600 A IL314600 A IL 314600A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- lung cancer
- small cell
- cell lung
- combined therapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263307533P | 2022-02-07 | 2022-02-07 | |
| US202263333597P | 2022-04-22 | 2022-04-22 | |
| PCT/CA2023/050151 WO2023147673A1 (en) | 2022-02-07 | 2023-02-06 | Combination therapy for use in treatment of non-small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314600A true IL314600A (en) | 2024-09-01 |
Family
ID=87553087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314600A IL314600A (en) | 2022-02-07 | 2023-02-06 | Combination therapy for use in treatment of non-small cell lung cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250108110A1 (https=) |
| EP (1) | EP4475885A4 (https=) |
| JP (1) | JP2025505652A (https=) |
| KR (1) | KR20240153627A (https=) |
| AU (1) | AU2023216333A1 (https=) |
| CA (1) | CA3243096A1 (https=) |
| IL (1) | IL314600A (https=) |
| MX (1) | MX2024009671A (https=) |
| WO (1) | WO2023147673A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034462B1 (ru) * | 2009-11-24 | 2020-02-11 | Алетиа Байотерапьютикс Инк. | Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований |
| US9822170B2 (en) * | 2012-02-22 | 2017-11-21 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
| CA3173786A1 (en) * | 2021-04-27 | 2022-10-27 | Mario Filion | Method for allowing immune cells infiltration in tumors |
-
2023
- 2023-02-06 MX MX2024009671A patent/MX2024009671A/es unknown
- 2023-02-06 CA CA3243096A patent/CA3243096A1/en active Pending
- 2023-02-06 EP EP23749327.5A patent/EP4475885A4/en active Pending
- 2023-02-06 AU AU2023216333A patent/AU2023216333A1/en active Pending
- 2023-02-06 IL IL314600A patent/IL314600A/en unknown
- 2023-02-06 JP JP2024546456A patent/JP2025505652A/ja active Pending
- 2023-02-06 US US18/729,922 patent/US20250108110A1/en active Pending
- 2023-02-06 WO PCT/CA2023/050151 patent/WO2023147673A1/en not_active Ceased
- 2023-02-06 KR KR1020247029988A patent/KR20240153627A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250108110A1 (en) | 2025-04-03 |
| MX2024009671A (es) | 2024-08-19 |
| EP4475885A4 (en) | 2026-02-18 |
| AU2023216333A1 (en) | 2024-08-22 |
| KR20240153627A (ko) | 2024-10-23 |
| JP2025505652A (ja) | 2025-02-28 |
| EP4475885A1 (en) | 2024-12-18 |
| WO2023147673A1 (en) | 2023-08-10 |
| CA3243096A1 (en) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2025002382A (es) | Anticuerpos antagonistas anti-tigit y anti-pd-l1 y usos de los mismos para el tratamiento del cancer | |
| PL3849534T3 (pl) | Połączenie dazatynibu i adagrasibu do stosowania w leczeniu niedrobnokomórkowego raka płuca | |
| IL276406A (en) | Osimertinib for use in the treatment of non-small cell lung cancer | |
| EA201491584A1 (ru) | Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor | |
| EA201290846A1 (ru) | Лучевая терапия, комбинированная с сенсибилизаторами гипоксической клетки | |
| WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| EP4442710A4 (en) | Combination of drugs for the treatment of non-small cell lung cancer | |
| EP4190173C0 (en) | METABOLIC THERAPY FOR CANCER | |
| LT4340842T (lt) | Sotorasibas, skirtas naudoti vėžio gydymui | |
| EP4440623A4 (en) | Polytherapy for the treatment of cancer | |
| IL308992A (en) | Cancer treatment in patients with soluble FR-alpha | |
| BR112018011196A2 (pt) | uso de pirimido-pirimidazinonas para tratar o câncer | |
| DK1971338T3 (da) | Kombination af ZD6474 og pemetrexed | |
| IL315441A (en) | Treatment methods for small cell lung cancer | |
| IL312249A (en) | Combination therapy for treating lung cancer | |
| IL314600A (en) | Combination therapy for use in treatment of non-small cell lung cancer | |
| GB202317288D0 (en) | Pyrrolopyridone derivatives useful in the treatment of cancer | |
| EA201391438A1 (ru) | Производные сулиндака, применение и получение указанных производных | |
| EP3817740A4 (en) | COMBINATION THERAPY WITH TARGETED TGF-B INHIBITION FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER | |
| BR112021018858A2 (pt) | Chiauranibe para tratamento de câncer de pulmão de células pequenas | |
| EA201501095A1 (ru) | Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли | |
| HK40116955A (en) | Combination therapy for use in treatment of non-small cell lung cancer | |
| IL326029A (en) | Treating non-small cell lung cancer with alectinib | |
| HK40068399A (en) | Osimertinib for use in the treatment of non-small cell lung cancer | |
| HK40043274A (en) | Osimertinib for use in the treatment of non-small cell lung cancer |